STAT+: Akero team, backed by Fairmount, launches new immunology company
FDA approves injectable Leqembi, another post-Makary reversal, and other biotech news from The Readout
Read the full articleYou might also wanna read
Biogen (BIIB) Unveils Efficacy Data for LEQEMBI Autoinjector at AAIC 2026
Related Stocks: BIIB
GuruFocus·4d ago
Biogen (BIIB) Sees Boost Following Early FDA Approval of Leqembi
Related Stocks: BIIB
GuruFocus·3d ago
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoria
Manila Times·2d ago
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik
Related Stocks: BIIB
GuruFocus·2d ago
CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population
Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to
Manila Times·1d ago
Biocon stock ticks up as Yesafili Biosimilar clinical data gets published in peer-reviewed journals
CEO Shreehas Tambe called the publications an important milestone for the company’s aflibercept biosimilar programme
thehindubusinessline.com·7d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.